Which thyroid antibody tests should be ordered to evaluate for hyperthyroidism, such as Graves disease?

Thyroid Antibody Testing for Hyperthyroidism

For suspected Graves' disease, order TSH receptor antibodies (TRAb) or thyroid-stimulating immunoglobulin (TSI)—either test alone is sufficient for diagnosis, as paired testing is redundant and costly. 1

Initial Diagnostic Approach

The evaluation of hyperthyroidism begins with serum TSH as the primary screening test, followed by free T4 and total T3 or free T3 levels when TSH is suppressed. 1 Once biochemical hyperthyroidism is confirmed (low TSH with elevated thyroid hormones), antibody testing helps differentiate the underlying cause.

Specific Antibody Tests for Hyperthyroidism

TSH Receptor Antibodies (TRAb or TSI)

Graves' disease is diagnosed by laboratory measurement of TSH receptor antibodies. 1 The evidence supports using either:

• TRAb (thyrotropin-binding inhibitory immunoglobulin): Detects antibodies that bind to the TSH receptor
• TSI (thyroid-stimulating immunoglobulin): Measures functional stimulating antibodies using bioassay or bridge immunoassay

Recent high-quality research demonstrates that TSI and TRAb show similar diagnostic performance for Graves' disease, with strong correlation between the two tests (rs = 0.844). 2 When analyzed collectively, these tests confirmed Graves' disease in 79% of cases and excluded it in 92.5% of non-Graves' cases. 2

A 2025 study examining over 189,000 patient encounters found that paired ordering of both TRAb and TSI is redundant, with good clinical and analytical agreement between the tests. 3 Discordance occurred in only 6.6-12.5% of paired orders, and TSI assays aligned better with confirmed Graves' disease diagnoses. 3 Paired testing resulted in a 31-325% increase in unnecessary costs. 3

Comparative Performance

The most recent evidence (2023) shows TSI has slightly better sensitivity (98.8%) compared to TRAb (96.6%) for diagnosing Graves' disease, though both demonstrate excellent specificity (96.4% and 97.1%, respectively). 4 However, the practical difference is minimal, and either test alone is appropriate for most clinical scenarios. 3

When Antibody Testing May Be Negative

Important caveat: TSH receptor antibody tests can be falsely negative in up to 21% of confirmed Graves' disease cases, particularly in patients with:

• Subclinical hyperthyroidism
• Normal radionuclide uptake
• Longer duration of thyrotoxicosis before testing
• Absence of goiter or Graves' ophthalmopathy 2

In ambiguous cases where toxic adenoma or toxic multinodular goiter is suspected, radioiodine uptake and scan can confirm the cause of thyrotoxicosis when antibody testing is inconclusive. 1

Thyroid Peroxidase Antibodies (Anti-TPO)

Anti-TPO antibodies are NOT primarily used to diagnose hyperthyroidism. While prevalent in Graves' disease patients, anti-TPO antibodies are more characteristic of Hashimoto's thyroiditis (hypothyroidism). 1

Anti-TPO testing may be warranted when thyroiditis is suspected as the cause of thyrotoxicosis, but anti-TPO positivity does not predict relapse after antithyroid drug treatment (relapse rates: 37.0% with anti-TPO vs 38.4% without). 5 However, anti-TPO presence at diagnosis may be associated with reduced relapse after radioactive iodine treatment (13.9% vs 24.6%). 5

Practical Testing Algorithm

1. Confirm biochemical hyperthyroidism: TSH, free T4, total T3 or free T3 1
2. Order ONE TSH receptor antibody test: Either TRAb OR TSI (not both) 3
3. If antibodies are positive: Graves' disease is confirmed 1
4. If antibodies are negative but clinical suspicion remains high: Consider radioiodine uptake and scan to differentiate Graves' disease from toxic nodular disease or thyroiditis 1

Do not routinely order anti-TPO antibodies for hyperthyroidism evaluation, as they do not reliably distinguish between causes of thyrotoxicosis. 1